Copolymer 1 (Glatiramer Acetate) in relapsing forms of multiple sclerosis: Open multicenter study of alternate-day administration

Clinical Neuropharmacology

Volumn 25, Issue 1, 2002, Pages 11-15

  Flechter, Shlomo ^a   Kott, Edna ^a   Steiner Birmanns, Bettina ^a   Nisipeanu, Puiu ^a   Korczyn, Amos D ^a  

^a ASSAF HAROFEH MEDICAL CENTER   (Israel)

Author keywords

Alternate day therapy; Copolymer 1; Glatiramer acetate; Mechanisms; Multiple sclerosis; Treatment

Indexed keywords

GLATIRAMER; MANNITOL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG FORMULATION; DRUG TOLERABILITY; DYSPNEA; FEMALE; FLUSHING; HEART PALPITATION; HUMAN; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RELAPSE; THORAX PAIN;

ADULT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PEPTIDES; RECURRENCE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0036178659     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200201000-00002     Document Type: Article

References (15)

1. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
2. Copolymer 1 reduces the relapse rate and improves disability in relapsing-remitting multiple sclerosis. Results of a phase III multicenter, double-blind, placebo-controlled trial
3. Intramuscular interferon: β-1a for disease progression in relapsing-remitting multiple sclerosis
4. The prisms study group prevention relapses and disability by interferon: β-1a subcutaneously in multiple sclerosis
5. Management of multiple sclerosis
6. Therapeutic advances: β-interferon for multiple sclerosis
7. Management of patients receiving interferon: β-1b for multiple sclerosis: Report of a consensus conference
8. Suppression of experimental allergic encephalomyelitis by Cop 1: Relevance to multiple sclerosis
9. Copolymer 1: From basic research to clinical application
10. Multiple sclerosis: Trial of a synthetic polypeptide
11. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis
12. A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis
13. Safety profile of Copolymer 1: Analysis of cumulative experience in the United States and Israel
14. Copolymer 1 in relapsing-remitting multiple sclerosis: A multicenter trial